Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Acceleron Pharma

- PMLiVE

Merck’s Winrevair granted MHRA approval to treat pulmonary arterial hypertension

The drug has been authorised for use in adults with moderate or marked limitations of physical activity

- PMLiVE

Merck shares positive phase 3 results for pulmonary arterial hypertension therapy

The progressive blood vessel disorder affects approximately 40,000 people in the US

- PMLiVE

Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension

Yuvanci is now the only single tablet combination therapy for PAH patients in Europe

- PMLiVE

Merck’s Winrevair receives EC approval to treat pulmonary arterial hypertension in adults

About 30,000 people in the EU are living with the progressive blood vessel disorder

- PMLiVE

Johnson & Johnson’s Yuvanci recommended by CHMP to treat pulmonary arterial hypertension

The rare form of pulmonary hypertension affects around 30,000 people in the EU

- PMLiVE

Merck’s pulmonary arterial hypertension therapy receives CHMP recommendation

Approximately 30,000 people in the EU are currently living with the rare blood disorder

- PMLiVE

Bristol Myers Squibb’s Reblozyl receives EC approval in myelodysplastic syndromes

The treatment is already approved in the EU to treat anaemia in adults with beta-thalassaemia

- PMLiVE

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...

Inizio

- PMLiVE

Merck’s Winrevair granted FDA approval to treat pulmonary arterial hypertension in adults

The rare blood vessel disorder affects approximately 500 to 1,000 people in the US every year

- PMLiVE

Johnson & Johnson’s Opsynvi granted FDA approval in pulmonary arterial hypertension

The rare form of pulmonary hypertension is responsible for up to 1,000 new cases in the US every year

- PMLiVE

Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.

Inizio

- PMLiVE

Janssen’s single tablet combination shows promise in phase 3 PAH study

Around 500 to 1,000 cases of pulmonary arterial hypertension are diagnosed each year in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links